RE:RE:RE:RE:RE:RE:RE:RE:AACR 2024 : Cancer vaccines get reintroduction with pathway
Further issues with the development of synthetically (chemically) manufactured mRNA vaccines focus on the manufacturing challenges. And this is, of course, the stability of the molecule, the scalability of the process, and also the robustness and the quality needed to be delivered at the end of a production. So, this all means one must have a good understanding of critical process parameters and what is challenging the production is that with these new molecules, there is no large scale industrial process. So basically, at the present one is coming from lab scale processes, that require scale up and a need to have a lot of know-how to scale up the manufacturing from the lab to commercial quantities.
Additionally, in the mRNA field is, there are a lot of intellectual property around, that requires navigation through the intellectual property landscape, particularly since significant legal challenges to mRNA intellectual property and processes are currently happening.
In contrast, the manufacture of ONCY's pelareorep has been scaled up to pivotal clinical trial / pre-commercial levels and ONCY has full ownership of the intellectual property that is involved in the clinical development and go-to-market strategies needed to launch pelareorep, without facing any of the impediments that mRNA vaccines currently face.